IL238654A0 - Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same - Google Patents
Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using sameInfo
- Publication number
- IL238654A0 IL238654A0 IL238654A IL23865415A IL238654A0 IL 238654 A0 IL238654 A0 IL 238654A0 IL 238654 A IL238654 A IL 238654A IL 23865415 A IL23865415 A IL 23865415A IL 238654 A0 IL238654 A0 IL 238654A0
- Authority
- IL
- Israel
- Prior art keywords
- fsh
- follicle
- making
- methods
- same
- Prior art date
Links
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 title 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 title 1
- 229940028334 follicle stimulating hormone Drugs 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 230000002101 lytic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726935P | 2012-11-15 | 2012-11-15 | |
PCT/US2013/070093 WO2014078533A1 (en) | 2012-11-15 | 2013-11-14 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
IL238654A0 true IL238654A0 (en) | 2015-06-30 |
Family
ID=50731688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL238654A IL238654A0 (en) | 2012-11-15 | 2015-05-06 | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140161767A1 (en) |
EP (1) | EP2920212A4 (en) |
JP (1) | JP2016506373A (en) |
KR (1) | KR20150122625A (en) |
CN (1) | CN105073779A (en) |
AU (1) | AU2013344701A1 (en) |
BR (1) | BR112015010943A2 (en) |
CA (1) | CA2910311A1 (en) |
HK (1) | HK1213923A1 (en) |
IL (1) | IL238654A0 (en) |
WO (1) | WO2014078533A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009518446A (en) * | 2005-12-07 | 2009-05-07 | メダレックス インコーポレーティッド | CTLA-4 antibody dose escalation regimen |
KR20210090298A (en) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | Antibody/drug conjugates and methods of use |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CN114150018A (en) | 2014-10-02 | 2022-03-08 | 威斯塔解剖学和生物学研究所 | Methods and compositions for treating cancer |
WO2016073456A1 (en) * | 2014-11-04 | 2016-05-12 | The Trustees Of The University Of Pennsylvania | Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor |
IT201600101852A1 (en) * | 2016-10-11 | 2018-04-11 | Abresearch Srl | FSH hormone receptor ligands in the diagnosis and treatment of tumors |
IT201600101870A1 (en) * | 2016-10-11 | 2018-04-11 | Abresearch Srl | FSH hormone receptor ligands in the diagnosis and therapy of neuroblastoma |
JP7226803B2 (en) * | 2016-10-11 | 2023-02-21 | オンコグリーン セラピューティクス エッセア | Ligands for FSH hormone receptors in tumor diagnosis and therapy |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN109957580A (en) * | 2019-05-07 | 2019-07-02 | 西北农林科技大学 | A method of expression human follicle-stimulating growth hormone (FSH) |
BR112022018994A2 (en) * | 2020-03-26 | 2022-11-29 | A28 Therapeutics Inc | LITHIC DOMAIN FUSION CONSTRUCTS, SIGNALING PATHWAY INHIBITORS AND METHODS OF PRODUCING AND USING THEM |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US20050287120A1 (en) * | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
US7122181B2 (en) * | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
WO2004042015A2 (en) * | 2002-11-01 | 2004-05-21 | Mayo Foundation For Medical Education And Research | Methods and vectors for controlling gene expression |
CA2713126C (en) * | 2008-01-24 | 2017-08-15 | Esperance Pharmaceuticals | Lytic domain fusion constructs and methods of making and using same |
WO2010045002A2 (en) * | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
WO2012050892A2 (en) * | 2010-09-29 | 2012-04-19 | Esperance Pharmaceuticals, Inc. | Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors |
-
2013
- 2013-11-14 BR BR112015010943A patent/BR112015010943A2/en not_active IP Right Cessation
- 2013-11-14 US US14/080,185 patent/US20140161767A1/en not_active Abandoned
- 2013-11-14 CN CN201380070595.1A patent/CN105073779A/en active Pending
- 2013-11-14 KR KR1020157015862A patent/KR20150122625A/en not_active Application Discontinuation
- 2013-11-14 AU AU2013344701A patent/AU2013344701A1/en not_active Abandoned
- 2013-11-14 EP EP13854675.9A patent/EP2920212A4/en not_active Withdrawn
- 2013-11-14 WO PCT/US2013/070093 patent/WO2014078533A1/en active Application Filing
- 2013-11-14 JP JP2015542776A patent/JP2016506373A/en active Pending
- 2013-11-14 CA CA2910311A patent/CA2910311A1/en not_active Abandoned
-
2015
- 2015-05-06 IL IL238654A patent/IL238654A0/en unknown
-
2016
- 2016-02-22 HK HK16101924.1A patent/HK1213923A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2920212A1 (en) | 2015-09-23 |
EP2920212A4 (en) | 2016-07-27 |
US20140161767A1 (en) | 2014-06-12 |
WO2014078533A1 (en) | 2014-05-22 |
HK1213923A1 (en) | 2016-07-15 |
BR112015010943A2 (en) | 2017-08-22 |
AU2013344701A1 (en) | 2015-05-28 |
JP2016506373A (en) | 2016-03-03 |
KR20150122625A (en) | 2015-11-02 |
CN105073779A (en) | 2015-11-18 |
CA2910311A1 (en) | 2014-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1213923A1 (en) | Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same (fsh)/ | |
IL272279A (en) | Chimeric antigen receptor and methods of use thereof | |
HK1213481A1 (en) | Dna antibody constructs and method of using same dna | |
ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
SG11201604719WA (en) | Dna antibody constructs and method of using same | |
ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
EP2862163A4 (en) | Methods and nodes for enabling and producing input to an application | |
EP2938632A4 (en) | Anti-granulysin antibodies and methods of use thereof | |
HK1203161A1 (en) | Peptides and methods of using same | |
SG11201507359SA (en) | Flavivirus neutralizing antibodies and methods of use thereof | |
EP2951217A4 (en) | Surfactants and methods of making and using same | |
HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
SG11201505891VA (en) | Catalyst compositions and methods of making and using same | |
HK1206249A1 (en) | Human autotaxin antibodies and methods of use (autotaxin) | |
EP2975062A4 (en) | Preparation and use of dimerized fusion protein | |
EP2988778A4 (en) | Clostridium difficile vaccine and methods of use | |
EP2804564A4 (en) | Coupling devices and methods of using the same | |
EP2951289A4 (en) | Placental membrane preparation and methods of making and using same |